



## The relationship between vitamin D and obesity

Sanja Soskić, Edita Stokić & Esmā R. Isenović

To cite this article: Sanja Soskić, Edita Stokić & Esmā R. Isenović (2014) The relationship between vitamin D and obesity, Current Medical Research and Opinion, 30:6, 1197-1199, DOI: 10.1185/03007995.2014.900004

To link to this article: <https://doi.org/10.1185/03007995.2014.900004>



Published online: 18 Mar 2014.



Submit your article to this journal [↗](#)



Article views: 1515



View related articles [↗](#)



View Crossmark data [↗](#)



Citing articles: 9 View citing articles [↗](#)

## Editorial

# The relationship between vitamin D and obesity

---

### Sanja Soskić

Institute of nuclear sciences 'Vinca', Laboratory for Radiobiology and Molecular Genetics, University of Belgrade, Belgrade, Serbia

### Edita Stokić

Clinical Center of Vojvodina, Medical Faculty in Novi Sad, Novi Sad, Serbia

### Esma R. Isenović

Institute of nuclear sciences 'Vinca', Laboratory for Radiobiology and Molecular Genetics, University of Belgrade, Belgrade, Serbia

---

#### Address for correspondence:

Prof. Dr. Esma R. Isenovic, Institute of nuclear sciences 'Vinca', University of Belgrade, Laboratory for Radiobiology and Molecular Genetics, Belgrade, Serbia.

isenovic@yahoo.com

---

#### Keywords:

Cardiovascular disease – Metabolic syndrome – Obesity – Type 2 diabetes – Vitamin D

---

Accepted: 26 February 2014; published online: 18 March 2014  
Citation: *Curr Med Res Opin* 2014; 30:1197–9

## Abstract

Currently, vitamin D deficiency and obesity are pandemic diseases and they are associated with cardiovascular (CV) disease, metabolic syndrome and type 2 diabetes mellitus (T2DM) and other diseases. Concentrations of 25-hydroxyvitamin D (25(OH)D) (25D) are considered as the best indicator of total body vitamin D stores. An association between reduced circulating 25D concentrations and obesity is well known, but the mechanisms are not totally clear. The role of vitamin D supplementation is still uncertain and prospective interventions will establish its influence, if any, in the treatment of obesity. Vitamin D deficiency is associated with the presence of a cardiometabolic risk profile in the obese. Future trials may establish a role for Vitamin D supplementation in individuals at increased CV risk.

The increase in obesity rates presents a major public health concern. In Europe, its prevalence is in the range of 10–25% in men and 10–30% in women<sup>1,2</sup>. Obesity is associated with a number of co-morbidities such as cardiovascular (CV) disease, hypertension, stroke, type 2 diabetes mellitus (T2DM), dyslipidemia, osteoarthritis and some cancers<sup>3,4</sup>.

The role of vitamin D in calcium and bone metabolism is well established. Today, vitamin D deficiency is a pandemic and has been implicated in several diseases including CV morbidity and mortality<sup>5–8</sup>, metabolic syndrome<sup>9–11</sup> and T2DM<sup>12–14</sup>.

Which proteins link vitamin D to obesity has been investigated in genetic studies<sup>15</sup>. There is also evidence that non-genomic mechanisms including protein expression, oxidative stress, inflammation and cellular metabolism are involved<sup>15</sup>. However, it is unlikely that vitamin D can cause weight loss although supplements may be associated with a small improvement in cardiovascular risk<sup>16–19</sup>. After absorption vitamin D is sequestered and stored in tissues (e.g. adipose and muscle)<sup>20</sup>. Radio-labeled vitamin D<sub>3</sub> has been injected into individuals and the highest levels of activity and radioactivity has been shown in adipose tissue<sup>21</sup>.

Serum concentrations of 25-hydroxyvitamin D (25(OH)D) (25D) are considered as the best indicator of total body vitamin D stores, and their value reflects the total dietary intake and exposure to ultraviolet radiation<sup>22</sup>. The association between reduced 25D concentrations and obesity is well known, but the mechanisms are not fully understood. The question still remains as to what the health consequences of these reduced 25D levels are, especially in obesity with dysfunctional adipose tissue and insulin resistance.

An inverse association between 25D levels and insulin resistance has been reported and lower vitamin D status was accompanied by higher glucose concentrations<sup>23–25</sup>. In patients with T2DM, it has been reported that glucose intolerance improves after vitamin D supplementation<sup>25,26</sup>. There is also an inverse association between 25D concentration and body mass index (BMI)<sup>27–30</sup>. The mechanisms involved in lower 25D concentrations in obese individuals are not fully described, but it is possible that sequestration of vitamin D metabolites in fat compartments decreases their bioavailability<sup>29</sup>.

Several clinical and epidemiological studies reported that obese subjects have lower serum concentrations of 25D with a negative correlation of vitamin D concentrations with BMI and waist circumference<sup>31,32</sup>. Additionally, fat mass is inversely associated with 25D levels<sup>33–38</sup>. Another explanation is that obese people have vitamin D deficiency because of less sun exposure due to a sedentary lifestyle<sup>37</sup>. A study involving 243 adults reported a decrease of 0.74 nmol/l of serum 25D per 1 kg/m<sup>2</sup> increase in BMI<sup>38</sup>.

The role of vitamin D supplementation is still uncertain. In Norway, 334 overweight/obese participants were treated with calcium plus vitamin D or placebo during 1 year; no change in weight was observed<sup>17</sup>.

Botella-Carretero *et al.* reported a negative correlation between serum 25D concentrations and serum triglycerides, as well as a positive association between serum 25D concentrations and serum high density lipoprotein cholesterol (HDL-C) concentrations<sup>39,40</sup>. Another study failed to find any effect of raising 25D levels on plasma lipids<sup>41</sup> while a similar study found that calcium and vitamin D supplementation resulted in decreased serum low density lipoprotein cholesterol levels<sup>42</sup>. As dyslipidemia is an important CV risk factor, there is a need for randomized controlled trials to clarify the possible effects of vitamin D on atherogenic dyslipidemia, especially in obese persons.

Several studies have proposed a relationship between vitamin D status and insulin resistance<sup>23,24,43</sup>. Pancreatic  $\beta$ -cells express vitamin D receptors, so a possible explanation is that vitamin D acts on these receptors<sup>44</sup> and in that way can indirectly influence calcium entering the  $\beta$ -cells<sup>45</sup>; thus vitamin D may affect insulin secretion.

There is evidence suggesting that vitamin D deficiency is a potential risk factor for CV disease<sup>46–49</sup>. Giovannucci *et al.* in a 10 year follow up clinical study found that men with vitamin D deficiency were at higher risk for myocardial infarction<sup>50</sup>. Wang *et al.* reported that vitamin D deficiency among participants with hypertension is related with a two-fold increased CV risk<sup>51</sup>.

Recently, Alhamad *et al.*<sup>52</sup> reported the findings of a study related to the vitamin D deficiency among the elderly. They found that in elderly people, lower serum vitamin D levels were inversely correlated with values of HbA<sub>1c</sub> (an index of glycemic control) and HDL-C. In addition, they show that after supplementation, improvement in vitamin D deficiency was small but significant.

In conclusion, vitamin D deficiency seems to promote the development of a more proatherogenic cardiometabolic risk profile in the obese as well in persons with increased fat mass. Future research may show that measurement of vitamin D levels can help to identify individuals at greater CV risk. This could be the basis for the design of future intervention trials in the obese.

## Transparency

### Declaration of funding

This work was supported by grant No. 173033 (to E.R.I.) from the Ministry of Education, Science and Technological Development of the Republic of Serbia.

### Declaration of financial/other relationships

S.S., E.S., and E.R.I. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article.

## References

1. James WP. The epidemiology of obesity: the size of the problem. *J Intern Med* 2008;263:336-52
2. Branca F, Nikoghosian H, Lobstein T. (eds) The Challenge of Obesity in the WHO European Region and the Strategies for Response. Summary. World Health Organization, 2007
3. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. *JAMA* 1999;282:1523-9
4. Clinical guidelines on the identification, evaluation, treatment of overweight and obesity in adults – the evidence report. National Institutes of Health. *Obes Res* 1998;6(Suppl 2):51-209S
5. Kienreich K, Tomaschitz A, Verheyen N, et al. Vitamin D and cardiovascular disease. *Nutrients* 2013;5:3005-21
6. Abu El Maaty MA, Hassanein SI, Hanafi RS, et al. Insights on vitamin D's role in cardiovascular disease: investigating the association of 25-hydroxyvitamin D with the dimethylated arginines. *J Nutr Sci Vitaminol (Tokyo)* 2013;59:172-7
7. Siadat ZD, Kiani K, Sadeghi M, et al. Association of vitamin D deficiency and coronary artery disease with cardiovascular risk factors. *J Res Med Sci* 2012;17:1052-5
8. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. *Hypertension* 2008;52:828-32
9. Khan H, Kunutsor S, Franco OH, et al. Vitamin D. Type 2 diabetes and other metabolic outcomes: a systematic review and meta-analysis of prospective studies. *Proc Nutr Soc* 2013;72:89-97
10. Ford ES, Ajani UA, Mcguire LC, et al. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. *Diabetes Care* 2005;28:1228-30
11. Hypponen E, Boucher BJ, Berry DJ, et al. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. *Diabetes* 2008;57:298-305
12. Cimbek A, Gursoy G, Kirnap NG, et al. Relation of obesity with serum 25 hydroxy vitamin D3 levels in type 2 diabetic patients. *J Res Med Sci* 2012;17:1119-23
13. Hossein-Nezhad A, Holick MF. Vitamin D for health: a global perspective. *Mayo Clin Proc* 2013;88:720-55
14. Manchanda PK, Bid HK. Vitamin D receptor and type 2 diabetes mellitus: growing therapeutic opportunities. *Indian J Hum Genet* 2012;18:274-5
15. Vinh Quoc Lu'o'ng K, Nguyen LT. The beneficial role of vitamin D in obesity: possible genetic and cell signaling mechanisms. *Nutr J* 2013;12:89. doi:10.1186/1475-2891-12-89
16. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. *Am J Clin Nutr* 2009;89:1321-7
17. Sneve M, Figenschau Y, Jorde R. Supplementation with cholecalciferol does not result in weight reduction in overweight and obese subjects. *Eur J Endocrinol* 2008;159:675-84
18. Boon N, Hul GB, Sicard A, et al. The effects of increasing serum calcitriol on energy and fat metabolism and gene expression. *Obesity (Silver Spring)* 2006;14:1739-46

19. Jorde R, Sneve M, Torjesen P, et al. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. *J Intern Med* 2010;267:462-72
20. Lumb GA, Mawer EB, Stanbury SW. The apparent vitamin D resistance of chronic renal failure: a study of the physiology of vitamin D in man. *Am J Med* 1971;50:421-41
21. Mawer EB, Backhouse J, Holman CA, et al. The distribution and storage of vitamin D and its metabolites in human tissues. *Clin Sci* 1972;43:413-31
22. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;357:266-81
23. Heaney RP, French CB, Nguyen S, et al. A novel approach localizes the association of vitamin D status with insulin resistance to one region of the 25-hydroxyvitamin D continuum. *Adv Nutr* 2013;4:303-10
24. Schotker B, Herder C, Rothenbacher D, et al. Serum 25-hydroxyvitamin D levels and incident diabetes mellitus type 2: a competing risk analysis in a large population-based cohort of older adults. *Eur J Epidemiol* 2013;28:267-75
25. Hutchinson MS, Figenschau Y, Almas B, et al. Serum 25-hydroxyvitamin D levels in subjects with reduced glucose tolerance and type 2 diabetes – the Tromsø OGTT-study. *Int J Vitam Nutr Res* 2011;81:317-27
26. Nazarian S, St Peter JV, Boston RC, et al. Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose. *Transl Res* 2011;158:276-81
27. Liel Y, Ulmer E, Shary J, et al. Low circulating vitamin D in obesity. *Calcif Tissue Int* 1988;43:199-201
28. Hyldstrup L, Andersen T, McNair P, et al. Bone metabolism in obesity: changes related to severe overweight and dietary weight reduction. *Acta Endocrinol (Copenh)* 1993;129:393-8
29. Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. *Am J Clin Nutr* 2000;72:690-3
30. Parikh SJ, Edelman M, Uwaifo GI, et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. *J Clin Endocrinol Metab* 2004;89:1196-9
31. Taheri E, Saedisomeolia A, Djalali M, et al. The relationship between serum 25-hydroxy vitamin D concentration and obesity in type 2 diabetic patients and healthy subjects. *J Diabetes Metab Disord* 2012; 11:16. doi:10.1186/2251-6581-11-16
32. De Pergola G, Nitti A, Bartolomeo N, et al. Possible role of hyperinsulinemia and insulin resistance in lower vitamin D levels in overweight and obese patients. *Biomed Res Int* 2013;2013:921348. doi:10.1155/2013/921348
33. Buffington C, Walker B, Cowan Jr GS, et al. Vitamin D deficiency in the morbidly obese. *Obes Surg* 1993;3:421-4
34. Hey H, Stokholm KH, Lund B, et al. Vitamin D deficiency in obese patients and changes in circulating vitamin D metabolites following jejunoileal bypass. *Int J Obes* 1982;6:473-9
35. Arunabh S, Pollack S, Yeh J, et al. Body fat content and 25-hydroxyvitamin D levels in healthy women. *J Clin Endocrinol Metab* 2003;88:157-61
36. Salekzamani S, Neyestani TR, Alavi-Majid H, et al. Is vitamin D status a determining factor for metabolic syndrome? A case-control study. *Diabetes Metab Syndr* 2011;4:205-12
37. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. *Am J Clin Nutr* 2004;80(6 Suppl):1678S-88S
38. Mcgill AT, Stewart JM, Lithander FE, et al. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. *Nutr J* 2008;7:1-5
39. Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, et al. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. *Clin Nutr* 2007;26:573-80
40. Stokić E, Tomić-Naglić D, Kovačev Zavišić B, et al. Obesity and vitamin D deficiency: trends to promote a more proatherogenic cardiometabolic risk profile. *Angiology* 2014; in press. doi:10.1177/0003319714528569
41. Wamberg L, Kampmann U, Stokkilde-Jorgensen H, et al. Effects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels – results from a randomized trial. *Eur J Intern Med* 2013;24:644-9
42. Major GC, Alarie F, Dore J, et al. Supplementation with calcium + vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. *Am J Clin Nutr* 2007;85:54-9
43. Chiu KC, Chu A, Go VL, et al. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. *Am J Clin Nutr* 2004;79:820-5
44. Tai K, Need AG, Horowitz M, et al. Vitamin D, glucose, insulin, and insulin sensitivity. *Nutrition* 2008;24:279-85
45. Pittas AG, Lau J, Hu FB, et al. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. *J Clin Endocrinol Metab* 2007;92:2017-29
46. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. *Arch Intern Med* 2008;168:1340-9
47. Reis JP, Von Muhlen D, Miller 3rd ER, et al. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. *Pediatrics* 2009;124:e371-9
48. Poole KE, Loveridge N, Barker PJ, et al. Reduced vitamin D in acute stroke. *Stroke* 2006;37:243-5
49. Katsiki N, Athyros VG, Karagiannis A, et al. Vitamin D deficiency, statin-related myopathy and other links with vascular risk. *Curr Med Res Opin* 2011;27:1691-2
50. Giovannucci E, Liu Y, Hollis BW, et al. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. *Arch Intern Med* 2008;168:1174-80
51. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. *Circulation* 2008;117:503-11
52. Alhamad HK, Nadukkandiyil N, El-Menyar A, et al. Vitamin D deficiency among the elderly: insights from Qatar. *Curr Med Res Opin* 2014;30:1189-96